Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Astra Wins MedImmune Auction; $15.6 Billion Price Tag Raises Eyebrows

Executive Summary

AstraZeneca's move to bolster its biologics portfolio through the acquisition of MedImmune for roughly $15.6 billion illustrates the increasingly high stakes of mergers in the biotech space

You may also be interested in...



Farewell To MedImmune: AstraZeneca Will Combine Large And Small Molecule Research

The company will integrate MedImmune, which has operated as the biologics research arm of AstraZeneca, amid an R&D and commercial restructuring.

Deals Of The Week: AstraZeneca/Vanderbilt, Medicago, OcellO/Merus

High-level executive changes at AstraZeneca continue pondering of where the British pharma turns next for growth – will it look to large-scale M&A again?

Infinity Regains Rights To Its Lead Program

Biotech pays nothing upfront to regain the Phase III HSP90 inhibitor, which is still on track in multiple clinical trials.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS048293

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel